A Critical Study on the Synthetic Medication Pattern in the Management of Rheumatoid Arthritis

Abstract

An inflammatory condition known as arthritis affects one or more joints in the body. The pathophysiology of rheumatoid arthritis (RA), a diverse ailment with a complicated and still poorly known pathogenesis, involves many different cell types in the destruction of the joints. Due to this complexity, clinical course and severity vary widely amongst patients and genetic and/or environmental factors may also impact them. In addition to the conventional synthetic disease-modifying anti-rheumatic drugs, biologics have demonstrated efficacy and safety in symptomatic relief, reducing bone loss, and maintaining the function, which has considerably improved the treatment of rheumatoid arthritis. Since current drugs periodically fail, only substantially treat the ailment or have unfavorable side effects. There are still unmet treatment requirements in rheumatoid arthritis despite the availability of a wide range of therapeutic choices and their combinations. Unfortunately, the ‘nonresponse’ pathways are still not fully understood, although they most definitely have to do with the covert variability of the pathophysiology of the disease. In this research, we will narrate the current and upcoming biological treatments and their cellular aims.